Phase II Cohort of Spinal Stereotactic Radiotherapy in Patients Using a MR LINAC

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05709782
Collaborator
(none)
40
1
2
30.1
1.3

Study Details

Study Description

Brief Summary

To learn whether giving spinal stereotactic radiosurgery (SRSS) that uses a more advanced imaging scan method called Magnetic Resonance imaging with a Linear Accelerator (MR-LINAC) during treatment will lead to improved responses to treatment and better quality of life. SRSS is radiation therapy given to the area around your spine.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Spine Radiosurgery
  • Device: Magnetic Resonance imaging
  • Radiation: MR-LINAC
Phase 2

Detailed Description

Primary objective:

• To determine the 6-month local control (LC) of the target site of treatment.

Secondary Objectives:
  • To determine the 6-month change in epidural tumor volume (by volumetric measurements where applicable)

  • To determine the 1-year local control of the target site

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase II Cohort of Spinal Stereotactic Radiotherapy in Patients Using a MR LINAC
Anticipated Study Start Date :
Jun 30, 2023
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group 1 (Therapeutic Cohort)

Participants in Group 1 will receive spine radiosurgery on the MR LINAC machine, along with imaging scans using the same machine.

Procedure: Spine Radiosurgery
scan

Device: Magnetic Resonance imaging
scan

Radiation: MR-LINAC
scan

Experimental: Group 2 (Imaging-only Cohort)

Participants in Group 2 will receive spine radiosurgery using a standard radiation therapy machine and have the opportunity to get imaging on the MR LINAC.

Procedure: Spine Radiosurgery
scan

Device: Magnetic Resonance imaging
scan

Outcome Measures

Primary Outcome Measures

  1. M. D. Anderson Symptom Inventory - Spine Tumor (MDASI-SP) questionnaires [through study completion; an average of 1 year]

    M. D. Anderson Symptom Inventory - Spine Tumor (MDASI-SP) 0 (symptom has not been present) to 10 (the symptom was as bad as you can imagine it could be) for each item.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
INCLUSION CRITERIA:
  1. Age ≥ 18 years old

  2. Radiographically documented disease of the spine within 4 weeks of registration (candidates with or without epidural disease allowed)

  3. Candidate for spine SRS/SBRT as determined by treating Radiation Oncologist or Multidisciplinary Spine Conference review

  4. Maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated allowed

  5. Diagnosis of cancer documented

  6. Motor strength ≥ 4 out of 5 in the extremity affected by the level of spinal disease planned for radiation

  7. Karnofsky Performance score (KPS) ≥ 40 or ECOG score ≤ 3

EXCLUSION CRITERIA:
  1. Patients with highly radiosensitive histologies likely to respond to conventional radiation therapy alone (ie lymphoma, multiple myeloma, etc)

  2. Patients who are unable to undergo MRI of the spine with contrast

  3. Patients who are pregnant

Contacts and Locations

Locations

Site City State Country Postal Code
1 M D Anderson Cancer Center Houston Texas United States 77030

Sponsors and Collaborators

  • M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Debra N. Yeboa, MD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT05709782
Other Study ID Numbers:
  • 2022-0589
  • NCI-2023-00663
First Posted:
Feb 2, 2023
Last Update Posted:
Feb 2, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 2, 2023